دورية أكاديمية
أعرض في EDS

Targeting human langerin promotes HIV-1 specific humoral immune responses.

التفاصيل البيبلوغرافية
العنوان: Targeting human langerin promotes HIV-1 specific humoral immune responses.
المؤلفون: Kervevan J; Vaccine Research Institute, Créteil, France, Inserm U955, Équipe 16, Créteil, France., Bouteau A; Baylor Institute for Immunology Research (BIIR), Vaccine Research Institute, Dallas, Texas, United States of America.; Institute of Biomedical Studies, Baylor University, Waco, Texas, United States of America.; Thomas Jefferson University, Department of Microbiology and Immunology, Philadelphia, Pennsylvania, United States of America., Lanza JS; Centre d'Immunophénomique, Aix Marseille Université, INSERM, CNRS, Marseille, France.; Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, INSERM, CNRS, Marseille, France., Hammoudi A; Vaccine Research Institute, Créteil, France, Inserm U955, Équipe 16, Créteil, France., Zurawski S; Baylor Institute for Immunology Research (BIIR), Vaccine Research Institute, Dallas, Texas, United States of America., Surenaud M; Vaccine Research Institute, Créteil, France, Inserm U955, Équipe 16, Créteil, France., Dieudonné L; Vaccine Research Institute, Créteil, France, Inserm U955, Équipe 16, Créteil, France., Bonnet M; College of Biomedical and Life Sciences, University of Cardiff, Cardiff, United Kingdom., Lefebvre C; Vaccine Research Institute, Créteil, France, Inserm U955, Équipe 16, Créteil, France., Hocini H; Vaccine Research Institute, Créteil, France, Inserm U955, Équipe 16, Créteil, France., Marlin R; CEA, Université Paris-Sud, Inserm, U1184 'Immunology of Viral Infections and Autoimmune Diseases' (IMVA), IDMIT Department, IBFJ, Fontenay-aux-Roses, France., Guguin A; Inserm U955 -Plateforme de Cytométrie, Institut Mondor de Recherche Biomédicale, UPEC, Créteil, France., Hersant B; Department of plastic and maxillo-facial surgery, Henri Mondor Hospital, Créteil, France., Hermeziu O; Department of plastic and maxillo-facial surgery, Henri Mondor Hospital, Créteil, France., Menu E; CEA, Université Paris-Sud, Inserm, U1184 'Immunology of Viral Infections and Autoimmune Diseases' (IMVA), IDMIT Department, IBFJ, Fontenay-aux-Roses, France.; MISTIC Group, Department of Virology, Institut Pasteur, Paris, France., Lacabaratz C; Vaccine Research Institute, Créteil, France, Inserm U955, Équipe 16, Créteil, France., Lelièvre JD; Vaccine Research Institute, Créteil, France, Inserm U955, Équipe 16, Créteil, France., Zurawski G; Baylor Institute for Immunology Research (BIIR), Vaccine Research Institute, Dallas, Texas, United States of America., Godot V; Vaccine Research Institute, Créteil, France, Inserm U955, Équipe 16, Créteil, France., Henri S; Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, INSERM, CNRS, Marseille, France., Igyártó BZ; Baylor Institute for Immunology Research (BIIR), Vaccine Research Institute, Dallas, Texas, United States of America.; Thomas Jefferson University, Department of Microbiology and Immunology, Philadelphia, Pennsylvania, United States of America., Levy Y; Vaccine Research Institute, Créteil, France, Inserm U955, Équipe 16, Créteil, France.; AP-HP, Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies Infectieuses, Créteil, France., Cardinaud S; Vaccine Research Institute, Créteil, France, Inserm U955, Équipe 16, Créteil, France.
المصدر: PLoS pathogens [PLoS Pathog] 2021 Jul 29; Vol. 17 (7), pp. e1009749. Date of Electronic Publication: 2021 Jul 29 (Print Publication: 2021).
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science, c2005-
مواضيع طبية MeSH: AIDS Vaccines/*immunology , Antigens, CD/*immunology , HIV-1/*immunology , Immunity, Humoral/*immunology , Langerhans Cells/*immunology , Lectins, C-Type/*immunology , Mannose-Binding Lectins/*immunology, Animals ; Humans ; Lymphocyte Activation/immunology ; Mice ; env Gene Products, Human Immunodeficiency Virus/immunology
مستخلص: The main avenue for the development of an HIV-1 vaccine remains the induction of protective antibodies. A rationale approach is to target antigen to specific receptors on dendritic cells (DC) via fused monoclonal antibodies (mAb). In mouse and non-human primate models, targeting of skin Langerhans cells (LC) with anti-Langerin mAbs fused with HIV-1 Gag antigen drives antigen-specific humoral responses. The development of these immunization strategies in humans requires a better understanding of early immune events driven by human LC. We therefore produced anti-Langerin mAbs fused with the HIV-1 gp140z Envelope (αLC.Env). First, we show that primary skin human LC and in vitro differentiated LC induce differentiation and expansion of naïve CD4+ T cells into T follicular helper (Tfh) cells. Second, when human LC are pre-treated with αLC.Env, differentiated Tfh cells significantly promote the production of specific IgG by B cells. Strikingly, HIV-Env-specific Ig are secreted by HIV-specific memory B cells. Consistently, we found that receptors and cytokines involved in Tfh differentiation and B cell functions are upregulated by LC during their maturation and after targeting Langerin. Finally, we show that subcutaneous immunization of mice by αLC.Env induces germinal center (GC) reaction in draining lymph nodes with higher numbers of Tfh cells, Env-specific B cells, as well as specific IgG serum levels compared to mice immunized with the non-targeting Env antigen. Altogether, we provide evidence that human LC properly targeted may be licensed to efficiently induce Tfh cell and B cell responses in GC.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: GZ, SZ, and YL are named inventors on patent applications held by Inserm and BIIR concerning Langerin targeting. All other authors have declared that no competing interest exist.
References: J Leukoc Biol. 2017 Jun;101(6):1393-1403. (PMID: 28270408)
Front Immunol. 2019 May 27;10:1134. (PMID: 31191525)
J Virol. 2017 Apr 13;91(9):. (PMID: 28202751)
Front Immunol. 2016 Nov 11;7:501. (PMID: 27891132)
Immunol Rev. 2010 Mar;234(1):177-98. (PMID: 20193019)
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2384-9. (PMID: 21262813)
J Allergy Clin Immunol. 2015 Nov;136(5):1387-97.e1-7. (PMID: 25962902)
J Immunol. 2006 Nov 15;177(10):7103-13. (PMID: 17082627)
Nature. 2007 Sep 27;449(7161):419-26. (PMID: 17898760)
Eur J Immunol. 2015 Mar;45(3):854-64. (PMID: 25487143)
J Virol. 2017 Jan 18;91(3):. (PMID: 27852854)
Eur J Immunol. 2016 Mar;46(3):689-700. (PMID: 26678013)
Front Immunol. 2017 Sep 08;8:1104. (PMID: 28943879)
Immunity. 2011 Jan 28;34(1):108-21. (PMID: 21215658)
J Immunol Methods. 2009 Apr 15;343(2):65-7. (PMID: 19100741)
Vaccine. 2011 Jun 15;29(27):4512-20. (PMID: 21514349)
Cancer Immunol Res. 2016 Oct;4(10):823-834. (PMID: 27485136)
Blood. 2010 Nov 11;116(19):3828-38. (PMID: 20668230)
Annu Rev Immunol. 2016 May 20;34:335-68. (PMID: 26907215)
PLoS Pathog. 2020 Nov 30;16(11):e1009025. (PMID: 33253297)
J Immunol. 2008 Apr 1;180(7):4742-53. (PMID: 18354198)
PLoS One. 2018 Nov 30;13(11):e0207794. (PMID: 30500852)
Sci Immunol. 2020 Mar 13;5(45):. (PMID: 32169954)
AIDS. 2013 Aug 24;27(13):2041-51. (PMID: 23615121)
Microb Pathog. 2013 May;58:35-44. (PMID: 23201532)
PLoS Pathog. 2019 Sep 9;15(9):e1008011. (PMID: 31498845)
J Virol. 2021 Jan 13;95(3):. (PMID: 33144321)
J Immunol. 2010 May 1;184(9):4842-51. (PMID: 20351191)
N Engl J Med. 2009 Dec 3;361(23):2209-20. (PMID: 19843557)
J Immunol. 2014 Sep 1;193(5):2416-26. (PMID: 25057007)
Immunity. 2008 Sep 19;29(3):497-510. (PMID: 18789730)
EMBO Rep. 2020 Feb 5;21(2):e49351. (PMID: 31833228)
J Immunol. 2015 Aug 15;195(4):1763-73. (PMID: 26170391)
Nat Commun. 2021 Apr 12;12(1):2147. (PMID: 33846309)
J Immunol. 2012 Mar 1;188(5):2146-55. (PMID: 22291181)
Cell Rep. 2016 Jan 5;14(1):43-54. (PMID: 26725118)
PLoS One. 2015 Sep 25;10(9):e0135513. (PMID: 26407317)
Immunity. 2014 Oct 16;41(4):592-604. (PMID: 25308333)
Nat Commun. 2019 Jun 21;10(1):2759. (PMID: 31227717)
Front Immunol. 2019 May 17;10:1086. (PMID: 31156636)
J Invest Dermatol. 2017 Sep;137(9):1905-1913. (PMID: 28457909)
J Exp Med. 2012 Jan 16;209(1):109-21. (PMID: 22213806)
J Immunol. 2013 Jan 1;190(1):66-79. (PMID: 23183897)
Immunity. 2019 May 21;50(5):1132-1148. (PMID: 31117010)
J Leukoc Biol. 2015 Apr;97(4):627-34. (PMID: 25516751)
Nat Immunol. 2014 Sep;15(9):856-65. (PMID: 25064073)
Eur J Immunol. 2017 May;47(5):818-829. (PMID: 28266028)
J Immunol. 2012 Sep 1;189(5):2645-55. (PMID: 22865916)
J Immunol. 2010 Oct 15;185(8):4724-8. (PMID: 20855870)
J Clin Invest. 2018 Oct 1;128(10):4387-4396. (PMID: 30148455)
معلومات مُعتمدة: R01 AI146420 United States AI NIAID NIH HHS
المشرفين على المادة: 0 (AIDS Vaccines)
0 (Antigens, CD)
0 (CD207 protein, human)
0 (Lectins, C-Type)
0 (Mannose-Binding Lectins)
0 (env Gene Products, Human Immunodeficiency Virus)
0 (gp140 envelope protein, Human immunodeficiency virus 1)
تواريخ الأحداث: Date Created: 20210729 Date Completed: 20211021 Latest Revision: 20211021
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8354475
DOI: 10.1371/journal.ppat.1009749
PMID: 34324611
قاعدة البيانات: MEDLINE
الوصف
تدمد:1553-7374
DOI:10.1371/journal.ppat.1009749